During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

The co-primary endpoints of overall response rate and overall survival were not met. The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ...

to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

We need to keep supporting this kind of research,” a Connecticut researcher and doctor said. “To see if we replicate these ...

As global markets grapple with inflation concerns and trade policy uncertainties, Asian tech stocks are capturing attention amid shifting economic dynamics. In this environment, identifying ...

于是参加了GC101 TIL细胞临床试验。幸运的是，该患者经TIL细胞输注6周后，肿瘤便缩小近一半（45%），并且疼痛情况得到改善，颈部淋巴结也得到消失。12周后，该患者经评估达到完全缓解（CR）状态，并在18周疗效评估时仍旧保持持续缓解状态。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...